Revvity (RVTY) Q4 2025 Financial Results Summary

2026-02-02 · Stocks · QuoteReporter

Revvity, Inc. (RVTY) Q4 2025 Financial Results Summary

Revvity, Inc. (NYSE: RVTY) reported its financial results for the fourth quarter and full year ended December 28, 2025, on February 2, 2026.

Fourth Quarter 2025 Highlights

Revenue:
$772 million, representing a 6% increase from $729 million in Q4 2024.
Organic growth of 4% when adjusted for foreign exchange and acquisitions.
Earnings Per Share (EPS):
GAAP EPS was $0.87, up from $0.78 in Q4 2024 (a 11.6% increase).
Adjusted EPS from continuing operations was $1.70, compared to $1.42 a year ago (an 19.8% increase).
Operating Income:
GAAP operating income from continuing operations was $112 million, down from $119 million in the previous year (a 5.9% decrease).
GAAP operating profit margin decreased to 14.5% from 16.3% year-over-year.
Adjusted Operating Income:
Adjusted operating income was $229 million, slightly up from $221 million a year ago (a 3.6% increase).
Adjusted operating profit margin was 29.7%, down from 30.3%.

Full Year 2025 Overview

Revenue:
Total revenue was $2.856 billion, compared to $2.755 billion in 2024 (a 3.7% increase).
Earnings Per Share (EPS):
GAAP EPS decreased to $2.07 from $2.20 in 2024 (a 5.9% decrease).
Adjusted EPS from continuing operations improved to $5.06 from $4.90 (a 3.3% increase).
Operating Income:
GAAP operating income grew to $357 million from $347 million (a 2.9% increase).
GAAP operating profit margin slightly decreased to 12.5% from 12.6%.
Adjusted Operating Income:
Adjusted operating income stood at $773 million, slightly down from $779 million (a 0.8% decrease).
Adjusted operating profit margin decreased to 27.1% from 28.3%.

Segment Performance

Life Sciences

Q4 2025:
Revenue was $382 million, up from $375 million (a 2% increase).
Adjusted operating income was $136 million, down from $138 million (a 1.4% decrease).
Adjusted operating margin: 35.6%, down from 36.9%.
Full Year 2025:
Revenue was $1.431 billion, an increase from $1.399 billion (a 2% increase).
Adjusted operating income was $458 million, down from $467 million (a 1.9% decrease).
Adjusted operating margin: 32.0%, down from 33.4%.

Diagnostics

Q4 2025:
Revenue was $390 million, a 10% increase from $355 million.
Adjusted operating income was stable at $91 million.
Adjusted operating margin decreased to 23.4% from 25.7%.
Full Year 2025:
Revenue reached $1.425 billion, up from $1.356 billion (a 5% increase).
Adjusted operating income decreased to $344 million from $354 million (a 2.8% decrease).
Adjusted operating margin decreased to 24.2% from 26.1%.

Additional Information

Dividends:
The report indicated that dividends paid were $3.838 million in 2025, compared to $8.832 million in 2024.
Share Repurchase:
No share repurchase activity was disclosed in the report.

Guidance for 2026

Revvity has initiated its full-year guidance for 2026, projecting:
– Total revenue in the range of $2.96 billion to $2.99 billion, with organic revenue growth of 2-3%.
– Adjusted earnings per share expected between $5.35 and $5.45.

These financial results highlight Revvity’s continued growth trajectory despite facing some challenges in profitability margins. The strong performance in the diagnostics segment suggests a robust demand, potentially leveraging growth opportunities moving forward.

	Three Months Ended		Twelve Months Ended
	December 28, 2025	December 29, 2024	December 28, 2025	December 29, 2024
Revenue	$772,056	$729,372	$2,856,051	$2,755,026
Cost of revenue	350,397	317,082	1,291,686	1,217,367
Selling, general and administrative expenses	251,734	244,332	991,890	994,074
Research and development expenses	58,176	49,208	215,840	196,844
Operating income from continuing operations	111,749	118,750	356,635	346,741
Interest income	-5,752	-9,828	-31,103	-73,190
Interest expense	23,513	22,781	92,185	96,278
Change in fair value of investments	7,972	6,017	11,456	-7,958
Other (income) expense, net	-5,544	5,222	15,820	15,485
Income from continuing operations, before income taxes	91,560	94,558	268,277	316,126
(Benefit from) provision for income taxes	-4,211	6,175	28,394	33,055
Income from continuing operations	95,771	88,383	239,883	283,071
Income (loss) from discontinued operations	2,593	6,262	1,318	-12,686
Net income	$98,364	$94,645	$241,201	$270,385
Diluted earnings per share:
Income from continuing operations	$0.85	$0.73	$2.06	$2.30
Income (loss) from discontinued operations	0.02	0.05	0.01	-0.10
Net income	$0.87	$0.78	$2.07	$2.20
Weighted average diluted shares of common stock outstanding	113,214	121,581	116,595	122,822
ABOVE PREPARED IN ACCORDANCE WITH GAAP

	December 28, 2025	December 29, 2024
Current assets:
Cash and cash equivalents	$919,860	$1,163,396
Accounts receivable, net	744,671	632,400
Inventories, net	379,497	367,587
Other current assets	195,719	186,225
Total current assets	2,239,747	2,349,608
Property, plant and equipment, net	479,249	482,217
Operating lease right-of-use assets, net	165,439	167,716
Intangible assets, net	2,347,003	2,640,921
Goodwill	6,613,493	6,463,619
Other assets, net	323,480	288,397
Total assets	$12,168,411	$12,392,478
Current liabilities:
Current portion of long-term debt	$588,828	$242
Accounts payable	185,464	167,463
Accrued expenses and other current liabilities	556,954	485,395
Total current liabilities	1,331,246	653,100
Long-term debt	2,631,236	3,150,476
Long-term liabilities	807,461	770,523
Operating lease liabilities	148,108	151,505
Total liabilities	4,918,051	4,725,604
Total stockholders’ equity	7,250,360	7,666,874
Total liabilities and stockholders’ equity	$12,168,411	$12,392,478
PREPARED IN ACCORDANCE WITH GAAP